A new multi-center U.S. study confirms that posterior sacroiliac (SI) joint fusion with a cortical allograft implant, LINQ, delivers significant, sustained pain relief for patients with chronic SI joint dysfunction.
The retrospective study evaluated 258 patients across six clinical sites who underwent the minimally invasive LINQ Fusion procedure between August 2019 and January 2024. At a mean follow-up of 1.75 years, patients reported a 6.01-point average reduction in Numeric Rating Scale (NRS) pain scores – well above the minimally clinically important difference (MCID) – with no serious adverse events reported.
Key findings from the study include:
Sustained pain relief: Mean NRS improved from 7.61 to 1.60 (6.01-point reduction)
Rapid onset: MCID achieved within 1 month (4.07-point drop)
No serious adverse events, transfusions, or overnight hospital stays
The study authors call for future prospective, randomized controlled trials to further validate these findings, assess fusion rates, and compare posterior and lateral approaches for outcomes, safety, and cost-effectiveness.
“At PainTEQ, our mission is to redefine relief for patients suffering from chronic SI joint pain,” said PainTEQ CEO Shanth Thiyagalingam. “The continued validation of LINQ through independent clinical studies reinforces the impact of our technology and supports our commitment to improving patient outcomes, expanding access, and shaping the future of SI joint care.”
A new multi-center U.S. study confirms that posterior sacroiliac (SI) joint fusion with a cortical allograft implant, LINQ, delivers significant, sustained pain relief for patients with chronic SI joint dysfunction.
The retrospective study evaluated 258 patients across six clinical sites who underwent the minimally invasive LINQ Fusion...
A new multi-center U.S. study confirms that posterior sacroiliac (SI) joint fusion with a cortical allograft implant, LINQ, delivers significant, sustained pain relief for patients with chronic SI joint dysfunction.
The retrospective study evaluated 258 patients across six clinical sites who underwent the minimally invasive LINQ Fusion procedure between August 2019 and January 2024. At a mean follow-up of 1.75 years, patients reported a 6.01-point average reduction in Numeric Rating Scale (NRS) pain scores – well above the minimally clinically important difference (MCID) – with no serious adverse events reported.
Key findings from the study include:
Sustained pain relief: Mean NRS improved from 7.61 to 1.60 (6.01-point reduction)
Rapid onset: MCID achieved within 1 month (4.07-point drop)
No serious adverse events, transfusions, or overnight hospital stays
The study authors call for future prospective, randomized controlled trials to further validate these findings, assess fusion rates, and compare posterior and lateral approaches for outcomes, safety, and cost-effectiveness.
“At PainTEQ, our mission is to redefine relief for patients suffering from chronic SI joint pain,” said PainTEQ CEO Shanth Thiyagalingam. “The continued validation of LINQ through independent clinical studies reinforces the impact of our technology and supports our commitment to improving patient outcomes, expanding access, and shaping the future of SI joint care.”
Copy to clipboard 
